February 15, 1990Cancer

Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenous 5-fluorouracil increase thrombogenicity markers in cancer patients?

Population

10 patients, 6 with head and neck cancer and 4 with gastrointestinal malignancies

Design

Cohort

Follow-up

postinfusion (4-5 days)

Authors

TKTimothy M. KuzelNorthwestern University BEBen EsparazNorthwestern University DGDavid GreenNorthwestern University

Discussion

Member takes

Implication

5-FU infusion was associated with coagulation activation; leaves open clinical thrombotic risk and needs prospective confirmation.

Structured PICO

Does intravenous 5-fluorouracil increase thrombogenicity markers in cancer patients?

Population

10 patients, 6 with head and neck cancer and 4 with gastrointestinal malignancies

Intervention

5-fluorouracil (1 g/m2/day) as a constant intravenous infusion over a 4-day or 5-day period (6 patients also received a single dose of 100 mg/m2 of cisplatin on day 1)

Outcome

Thrombogenicity assessed by fibrinopeptide A (FpA), protein C activity (PCa), protein C antigen (PCag), and free protein S antigen (PSag)surrogate

Intravenous 5-fluorouracil infusion is associated with activation of coagulation, potentially explaining the risk of acute myocardial infarction in patients receiving this chemotherapy.

Cite This Study

Kuzel et al. (1990) studied this question.

synapsesocial.com/papers/6a22902df4540fbb24542245 https://doi.org/10.1002/1097-0142(19900215)65:4<885::aid-cncr2820650410>3.0.co;2-h

View Full Paper

Ask AI

Bookmark

Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider